ABSTRACT BACKGROUND: Certain herbal medicines have been reported to be effective in the treatment of psychiatric conditions, and combination treatment with drugs and herbal medicines has been reported to be useful in enhancing treatment efficacy and reducing recovery time and adverse events (AEs).
INTRODUCTION
Cognitive deficits have been found to remain stable in ambulatory patients with schizophrenia, regardless of changes in clinical state. 1 The neurocognitive performance of patients with schizophrenia is closely correlated with several key outcome domains (eg, the development of new social skills, the ability to function independently in the community). Neurocognitive performance is viewed as a limiting factor to treatment success and rehabilitation. 2,3 It has been viewed as a key factor in schizophrenia pathology. In clinical studies, 4,5 cognitive symptoms (eg, impaired performance on the backward masking, span of apprehension, Wisconsin Card Sorting tasks) were found to be significantly related to negative symptoms (ie, diminution or loss of normal functions) but no clear association was found between positive symptoms (ie, excess or distortion of normal functions) and neurocognitive deficits. Hawkins et al ~ reported that schizophrenic patients with negative symptoms had significantly reduced (P < 0.01) cognitive function compared with patients without negative symptoms. Both syndromes are considered to be more resistant to psychopharmacologic interventions and to affect the psychosocial outcome to a greater degree than positive symptoms] Along with cognitive performance, negative symptoms are among the top informative bng-term prognostic outcome factors to consider in patients with schizophrenia. 8 Additionally, patients with a preponderance of negative symptoms might exhibit a generalized cognitive deficit (eg, memory, verbal fluency). However, cognitive improvement has been reported to ameliorate some of the difficult-to-treat negative symptoms. 9 In comparison with conventional antipsychotics, atypical antipsychotic drugs t~.ve some advantages: they have greater efficacy against both positive and negative symptoms, l° and they reduce the incidence of extrapyramidal symptoms (EPS) and tardive dyskinesia. ll Studies 12,13 have reported that atypical ant!psychotic drugs have greater efficacy against neurocognitive deficits, termed veurocogvitive adva,etage, and have reported improvements in cognition after switching patients from conventional to atypical antipsychotic drugs.
Some herbal medicines have been reported to be effbctive in the treatment of psychiatric conditions, and combination treatment with drugs and herbal medicines has been reported to be useful in enhancing efficacy and in reducing both recovery time and adverse events (AEs). 14 Traditional Chinese medicine (TCM) has been found to be significantly more effective than ant!psychotic drugs in treating anxiety and depression, while at the same time, preventing psychomotor inhibition. 15 According to TCM, schizophrenia is a syndrome caused by a yin-yang imbalance characterized by spleen and stomach weakness and inadequate kidney yin. > Herbal preparations such as warm-supplementing kidney yang (V4TSKY) or strong kidney yin is believed to improve deficits associated with schizophrenia. ~XrSKY comes in capsule form, and each capsule contains 13 Hefba epimedii has been reported to increase hypothalamic monoamine neurotransmitter concentrations in aging male rats and improve learning and memory in aging rats and mice. 21 It can also inhibit the activities of acetylcholine in both brain tissue and whole blood in mice. el Epimedium polysaccharides might improve the body's regulation of neuroimmunologic effects and could delay senilitye2; they may also improve cognition and negative symptoms in schizophrenic patients.
The purpose of this study was to investigate the effectiveness and tolerability of \VSKY added to risperidone in improving cognitive impairment and negative symptoms fie, cognitive function) in patients with schizophrenia. All raters underwent interrater reliability training using training modules. Intraclass correlation coefficients were >0.85 for all objective scales.
PATIENTS AND METHODS

PATIENTS
This study was approved by the hospitals' institutional review boards, and all patients gave written informed consent. If the patients were not able to give consent, family members provided consent. The study protocols conformed to the principles of tile Declaration of Helsinki. 2s All examinations and assessments were free of charge, and compensation fur transportation and telephone fees/charges during the study period was provided.
The KXTSKY capsules and placebo capsules were distributed by the Pharmacy Department of Third Renmin Hospital in accordance with the standards of the Chinese Food and Drug Supervision Bureau. The study drug was a 0.3 g 13-herb combination capsule. The placebo capsules contained 0.3 g of starch and were identical in appearance to the study drug.
The investigators were blinded to the randomization schedule during the study. However, individual treatment codes, indicating the treatment group for each patient, were available to the investigators. The treatment codes were disclosed only in the case of a medical emergency (ie, when appropriate management of the patient required drug treatment disclosure).
During the screening period, the patients underwent physical examination, ECG, hematologic and urine testing, blood chemistry screening (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, globulin, direct bilirubin, total bilirubin, urea, creatinine, uric acid, glucose, total cholesterol, and triglyceride), and scale assessment. The screenings were carried out by normal procedure. After screening, patients were randomized to receive ~XrSKY or placebo added to risperidone using SAS software version 8.2 (SAS Institute Inc., Cary, North Carolina). The x~TSKY and placebo capsules were randomly nmnbered from 1 to 140. Patients received a number according to the time they entered the trial (ie, patient 1 received drug 1; patient 2 received drug 2). The patients were assigned to a clinical investigator and scheduled to see the same clinical investigator for consultation and assessments (PANSS, Scale for the Assessment of Negative Symptoms [SANS], 29 [scale grading ranges from 1~ with 1 absent, 2 slight, 3 mild, 4 moderate, 5 slight severe, 6 severe, and 7 very severe] arid the HAM-D-17) to evaluate symptoms and cognitive functions during psychiatric clinical visits at the end of weeks 2, 4, and 8. A response rate was defined as a >50% reduction score from baseline on the PANSS, a >30% reduction score (from baseline) on the SANS, or a >50% reduction score (from baseline) on the HAM-D-17.
At each visit, patients were questioned whether they had experienced any healthrelated issues since the previous visit and were also assessed using the Treatment Emergent Symptoms Scale (TESS), 3° (scale grading ranges from 0 4 with 0 absent, 1 slight, 2 mild, 3 moderate, and 4 severe). The patients were instructed to report AEs at a W time during the study. Compliance was determined by medication count conducted by an investigator (Z.C., X.W., or H.W.). Noncompliance was determined if drug administration rate was <75%. At the final visit, physical examination, ECG, hematologic and urine testing, and blood chemistry screening were repeated. Additionally, a final assessment was completed at the end of week 8 or at the end point (ie, if the patient did not complete the study).
Patients who had been receiving nondepot antipsychotic treatment underwent a 2-to 7-day washout period before randomization. Because of the perceived ef}bcts of psychotherapy, initiation of psychotherapy was prohibited during the study.
TR~'ATMERT
~TSKY 0.9 g TID (morning, noon, and evening) or placebo was administered for 8 weeks. Risperidone was administered as ~bllows: 1 mg QN from day 1 to day 4; 1 mg BID (noon and evening) from day 5 to day 9; and from day 10 to the end point, the risperidone dosage (<8 mg/d) for each patient was adjusted according to the clinical judgment of the research psychiatrists. Anticholinergic medication (biperiden hydrochloride <8 mg/d) was administered if EPS were present at study inclusion or had developed during the course of treatment. Concomitant lorazepam (<4 rag) and zopiclone (<15 mg) were allowed to counteract agitation and sleep problems; these drugs had to be discontinued >24 hours prior to neurocognitive testing to reduce threats to validity. Antidepressants, mood stabilizers, psychostimulants, and antipsychotic drugs other than the study drugs were not allowed during the study.
STUDY ASSESSMENTS
Cognitive Function
The Wisconsin Card Sorting Test (WCST), 31,32 a measure of cognitive function (including executive function, abstraction, and working memory) was used to assess the ability to generate hypotheses, establish response sets, and fluently shift sets. 
Effectiveness a**d 7blerability
The patients were assessed at baseline and weeks 2, 4, and 8. The primary effectiveness measures were the scores on the PANSS and SANS. Secondary effectiveness measures included the scores on the Social Disability Screening Schedule (SDSS) 34-a 10-item scale--(scale grading ranges from 0~ with 0 absent, 1 moderate, and 2 sever<), HAM-D-17, and positive and general psychopathology PANSS subscales.
Tolerability was measured by vital signs, weight, ECG, and laboratory findings as well as by the assessments using the TESS, Abnormal Involuntary Movement Scale (AIMS), and RSESE scales.
Extrapyramidal AEs were assessed weekly using the AIMS 35 designed to measure medicine-induced involuntary movements (scale grading ranges from 0 4 with 0 none, 1 minimal, 2 mild, 3 moderate, and 4 severe) and the RSESE. AEs were assessed by patient interviews conducted at each clinic visit and also by the TESS scores.
STATISTICAL ANALYSES
The primary analyses were perfbrmed on an intent-to-treat basis and included all patients who were randomly assigned to treatment and received study medication. All end point analyses were conducted using the last-observation-carried-forward (LOCF) methodology (ie, the last available visit was used as the end point). Within-group changes from baseline to end point (LOCF) were analyzed using the Wilcoxon signed rank test. Between-group comparisons of change from baseline were analyzed by analysis of covariance, using investigation site, baseline value, and age, which were used as covariares in the model. Analyses of the primary efficacy variables (PANSS and SANS) were performed using visit wise (observed cases [OCsJ) and LOCF data set. A ){2 test was used to compare the proportion of positive treatment responses on the PANSS and SANS between the 2 groups. The Fisher exact test or the Z 2 test was used to compare AEs as appropriate. All statistical tests were 2-tailed, with a significance level ofP < 0.05. SPSS version 12.0 for Windows (SPSS Inc., Chicago, Illinois) was used for the statistical analyses. A power analysis was not performed.
RESULTS
PATIENT CHARACTERISTICS
Of the 140 patients who were screened, :120 patients (62 males, 58 ~bmales; mean 
COGNITIVE FUNCTION
Significant within-group improvement over time in WCST scores was observed for all parameters (number of completed categories, nmnber of perseverative responses, number of perseverative errors, total number of errors, and number of unique errors) in the WSKY group and in the number of completed categories, nmnber of perseverative responses, and total number of errors in the placebo group from baseline m the end point (all, P < 0.01) ( Table II) .
The xX/CST scores were similar in the 2 groups at baseline. The WSKY group significantly improved compared with the placebo group at end point in the number of completed categories (P 0.019), perseverative responses (P 0.041), perseverative errors (P 0.040), and total errors (P 0.049) (Table liD. 
EFFECTIVENESS ANALYSES
PANSS and SANS scores improved significantly from baseline to end point in both the WSKY and placebo groups (all, P < 0.001) ( Figure 1) ; however, there were no significant between-group differences in the PANSS or SANS scores. Improvements in the PANSS and SANS scores were not significantly different between the 2 groups at week 8 in the OC or at end point (LOCF) (F 3.328, P 0.071 and F 0.444, P 0.516, respectively) ( Figure 1 ).
For the PANSS and SANS scores, the response rates in the WSKY group were significantly higher compared with those in the placebo group for both the LOCF and the completers or at the end point (week 8) analyses (Figure 2 ). The response rates (LOCF) for the PANSS scores in the WSKY and placebo groups were 55.0% and 35.0/%, respectively (P 0.028), while the SANS scores were 63.3% and 45.0% (P 0.044) and the HAM-D-17 scores were 35.0% and 45.0% (P 0.264). For study completers, the response rates of the WSKY and placebo groups for the PANSS scores were 56.9% and 36.2%, respectively (P 0.026), while the SANS scores were 63.8% and 44.8% (P 0.040).
The reductions in the SDSS scores and the HAM-D-17 scores from baseline to end point (LOCF) were significantly higher in the ~vVSKY group compared with the placebo group (F 4.177, P 0.044 and F 5.911, P 0.017, respectively).
TOLERABILITY ANALYSES
WSKY or placebo added to risperidone were both well tolerated. Treatmentemergent AEs were reported in a similar number of patients in the WSKY and placebo groups (32 [53.3%] vs 34 [56.6%], respectively). AEs noted in >3% of the patients in Table I . Baseline demographic and clinical characteristics of the study patients (N = 120). Unless otherwise noted, data are mean (SD). There were no significant between-group differences. either group are illustrated in Table IV . No significant between-group differences were observed in regard to AE incidence. No serious or intolerable AEs were noted. No significant between-group differences were noted in changes in vital signs or laboratory findings, inchding ECGs. The changes in scores from baseline to end point on the AIMS and RSESE were not significantly dif}erent between the groups (F 1.021, P 0.314 and F 2.524, P 0.115, respectively). No treatment diff':fence was detected in the adjunctive use of anticholinergic agents between the 2 groups (~VSKY 63.3%,, placebo 80.0%). phrenia, cog,eitive fu~ectio~e, cognition, warm-supplemeeltivg kideley yavg, WSKY, and teegative symptoms did not find any studies examining the effects of'WSKY on cognitive impairment and negative symptoms in patients with schizophrenia. Our study found that at end point (LOCF), significant improvements were found in the \VCST scores in the number of completed categories, perseverative responses, perseverative errors, and total errors in the \VSKY group compared with the placebo group. The response rates for both LOCF and study completers on the PANSS and SANS were significantly higher in the ~'SKY group compared with the placebo group. However, the improvements in the PANSS and SANS scores were not significantly different between the 2 groups in the OC or at end point (LOCF). TreatmenFemergent AEs were reported in a comparable number of patients in the 2 groups. No significant differences in the AEs noted in >5% of the patients were found between the groups, and no serious or intolerable AEs were noted in either group. The changes in scores from baseline to end point on the AIMS and RSESE were similar in the 2 groups. No treamlent differences were found in the a.djuncdve use of andcholinergic ~.gents. Larger, controlled studies for longer durations are needed to evaluate the true effectiveness of VJSKY in the treatment of schizophrenia.
WSKY Group
LIMITATIONS
Because of limited literature, we might have tolerated the pharmacologic actions of some compositions of WSKY. In addition, the small sample size and the short duration of this study should also be considered limitations.
CONCLUSIONS
The results of this study suggest that ~SKY added to risperidone significantly improved the number of completed categories, perseverative responses, perseverative errors, and total errors on the ~VCST compared with placebo added to risperidone in these patients. The response rates in the ~SKY group for the PANSS and SANS scores were significantly higher than those in the placebo group. All treatments were generally well tolerated.
